The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
Competition is looming from Novartis and Roche but the latest results from Spinraza show that Biogen still has a strong case to make for the SMA therapy.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.